TD Cowen initiated coverage of Maze Therapeutics (MAZE) with a Buy rating and no price target The company’s MZE829, and oral APOL1 inhibitor, ...
Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the ...
Mit Blick auf den KI-Nachfrage-Ausblick lässt ein Bericht der Investmentbank TD Cowen aufhorchen: Microsoft hat demnach ...
Eli Lilly (LLY) and Novo Nordisk (NVO) to dominate as TD Cowen lifts 2030 sales forecast for GLP-1 class of obesity/ diabetes ...
A live webcast of the presentation may be accessed on the Investors section of the argenx website at argenx.com/investors. A replay of the webcast will be available on the argenx website for ...
TD Cowen cut shares of Akamai Technologies (NASDAQ:AKAM – Free Report) from a buy rating to a hold rating in a report issued ...
TD Cowen was established in 1918 as a bond trading firm and quickly expanded into clearing and execution services. By the 1970s, it had carved a niche in railroad bonds and grown a solid research ...
MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced ...
A live webcast can be accessed under "Events & Presentations” in the Investors & Media section of the Xilio Therapeutics ...
TD Cowen raised the firm’s price target on DraftKings (DKNG) to $60 from $51 and keeps a Buy rating on the shares. The firm raised its ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results